Why does glucose accumulate in the urine of diabetics

What does urine glucose testing measure? What does urine glucose testing involve? To perform the test:. Author: myDr. What is Lyme Disease? What is Hereditary Haemorrhagic Telangiectasia? What is a PET Scan? Norman Swan Gastrointestinal Health May 7, ,. What Happens if a Hernia is Left Untreated?

Symptoms May 3, ,. Previous article Blood donations. Next article Cataracts. We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. However, you may visit "Cookie Settings" to provide a controlled consent. Cookie Settings Accept All.

Manage consent. Without enough insulin, your body can't use sugar properly for energy. This prompts the release of hormones that break down fat as fuel, which produces acids known as ketones. Excess ketones build up in the blood and eventually "spill over" into the urine. Uncommonly, diabetic ketoacidosis can occur if you have type 2 diabetes.

In some cases, diabetic ketoacidosis may be the first sign that you have diabetes. Diabetic ketoacidosis is treated with fluids, electrolytes — such as sodium, potassium and chloride — and insulin.

Perhaps surprisingly, the most common complications of diabetic ketoacidosis are related to this lifesaving treatment. Left untreated, the risks of diabetic ketoacidosis are much greater. Diabetic ketoacidosis can lead to loss of consciousness and, eventually, death. Diabetes complications are scary. But don't let fear keep you from taking good care of yourself. These transporters control glucose transport and reabsorption in several tissue types, including the proximal renal tubule, small intestine, blood-brain barrier, and peripheral tissues Table.

SGLTs, on the other hand, mediate active transport of glucose against a concentration gradient by means of cotransport with sodium. This predominant role of SGLT2 in renal reabsorption of glucose raises the prospect of therapeutically blocking this protein in patients with diabetes.

In examining disorders involving renal glucose transport, gene mutations within SGLTs lead to inherited disorders of renal glucosuria, including familial primary renal glucosuria FRG and glucose-galactose malabsorption GGM. FRG, an autosomal recessive or autosomal dominant disorder resulting from several different SGLT2 mutations, is characterized by persistent glucosuria in the absence of hyperglycemia or general renal tubular dysfunction.

Even the most severe form of FRG type O , where nonfunctioning mutations within the SGLT2 gene result in a complete absence of renal tubular glucose reabsorption, is associated with a favorable prognosis.

Because FRG is generally asymptomatic, affected individuals are identified through routine urinalysis. GGM, a more serious autosomal recessive disease caused by mutation of the SGLT1 transporter, is characterized by intestinal symptoms that manifest within the first few days of life and result from failure to absorb glucose and galactose from the intestinal tract. The resultant severe diarrhea and dehydration may be fatal if a glucose- and galactose-free diet is not initiated.

In some patients with GGM, glucosuria is present but typically mild, while in others, no evidence of abnormal urinary glucose excretion exists, affirming the minor role of SGLT1 in renal glucose reabsorption of glucose. Gene mutations involving GLUTs are associated with more severe consequences, as these transporters are more widespread throughout the major organ systems.

Compared with SGLT2 and SGLT1, which are present mostly in the renal system, GLUT2 is a widely distributed facilitative glucose transporter that has a key role in glucose homeostasis through its involvement in intestinal glucose uptake, renal reabsorption of glucose, glucosensing in the pancreas, and hepatic uptake and release of glucose. Because GLUT2 is involved in the tubular reabsorption of glucose, glucosuria is a feature of the nephropathy.

While renal glucose reabsorption is a glucose-conserving mechanism in normal physiologic states, it is known to contribute to hyperglycemia in conditions such as T2DM. Diabetes has become the most common single cause of endstage renal disease ESRD in the United States and Europe; this is most likely due to several evolving factors, including an increased prevalence of T2DM, longer life spans among patients with diabetes, and better formal recognition of renal insufficiency.

ESRD spending represents 6. The epidemic growth in ESRD cases has led to skyrocketing utilization of healthcare resources. Since undetected T2DM may be present for many years, a higher proportion of individuals with T2DM vs type 1 diabetes mellitus have microalbuminuria and overt nephropathy shortly after diagnosis. As interventions for coronary artery disease continue to improve, however, more patients with T2DM may survive long enough to develop renal failure. Increasing evidence demonstrates that the onset and course of diabetic nephropathy may be significantly altered by several interventions eg, tight glucose control, use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers , all of which have their greatest impact if instituted early.

As such, annual screening for microalbuminuria is critical since it leads to early identification of nephropathy. Well-known data from the Diabetes Control and Complications Trial and the United Kingdom Prospective Diabetes Study established that intensive glycemic control may significantly reduce the risk of developing microalbuminuria and overt nephropathy.

The observed reduction in nephropathy is important, since indices of renal impairment are strongly associated with future risk of major vascular events, ESRD, and death in patients with diabetes. The regulation of glucose production, uptake, reabsorption, and elimination is handled by several organs, most notably historically the pancreas and liver. Under normal circumstances, glucose filtered by glomeruli is completely reabsorbed, but in conditions of hyperglycemia or reduced resorptive capacity, glucosuria may occur.

Hyperglycemia in turn detrimentally affects the kidneys by damaging glomeruli, ultimately causing microalbuminuria and nephropathy.

Author disclosure: Dr Triplitt reports being a consultant or a member of the advisory board for Roche and Takeda Pharmaceuticals. Authorship information: Concept and design; drafting of the manuscript; and critical revision of the manuscript for important intellectual content. Institute for Value-Based Medicine. The postprandial state Classically, metabolic studies have usually been undertaken in the post-absorptive state i.

Renal glucose reabsorption In addition to releasing glucose into the circulation by synthesizing new glucose molecules via gluconeogenesis and its utilization of glucose, the kidney can also influence glucose homeostasis by returning glucose to the circulation via the reabsorption of glucose from glomerular filtrate. Fig 1. The kidney in diabetes mellitus All of the ways in which the kidney normally affects glucose homeostasis are altered in patients with diabetes mellitus.

Renal gluconeogenesis in the post-absorptive state Consistent with numerous studies in diabetic animal models 38 — 44 , patients with T2DM have an increased release of glucose into the circulation by the kidney in the fasting state Postprandial renal glucose release After meal ingestion, renal glucose release increases to a greater extent in people with T2DM than in people with normal glucose tolerance Renal glucose uptake In addition to increased glucose production, renal glucose uptake is increased in both the post-absorptive and postprandial states in patients with T2DM 45 , Renal glucose reabsorption It is well recognized that glucosuria in diabetic patients does not occur at plasma glucose levels that would normally produce glucosuria in non-diabetic individuals Therapeutic implications Inhibitors of SGLT2 are currently undergoing clinical trials in patients with T2DM as a novel means of reducing hyperglycaemia.

References 1. Bergman H, Drury DR. The relationship of kidney function to the glucose utilization of the extra abdominal tissues. Am J Physiol. Control of blood sugar in insulin-dependent diabetes: comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion, and intensified conventional insulin therapy. N Engl J Med. Physical exercise and fuel homeostasis in diabetes mellitus.

Determination of Krebs cycle metabolic carbon exchange in vivo and its use to estimate the individual contributions of gluconeogenesis and glycogenolysis to overall glucose output in man. J Clin Invest. Gerich JE. Control of glycaemia. Baillieres Clin Endocrinol Metab. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UKPDS 33 Lancet. Long-term follow-up after tight control of blood pressure in type 2 diabetes.

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. Physiology of glucose homeostasis. Diabetes Obes Metab.

Effects of physiological hyperinsulinemia on systemic, renal, and hepatic substrate metabolism. Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans. Contributions of gluconeogenesis to glucose production in the fasted state.

Renal glucose production and utilization: new aspects in humans. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. Renal substrate exchange and gluconeogenesis in normal postabsorptive humans.

Am J Physiol Endocrinol Metab. Human kidney and liver gluconeogenesis: evidence for organ substrate selectivity. Insulin regulation of renal glucose metabolism in humans. Relative importance of liver, kidney, and substrates in epinephrine-induced increased gluconeogenesis in humans. Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Role of the human kidney in glucose counterregulation.

Renal glucose production compensates for the liver during the anhepatic phase of liver transplantation. Hepatorenal glucose reciprocity in physiologic and pathologic conditions.

Diabetes Nutr Metab. Brenner BM. Philadelphia: W. Saunders Company; Active sugar transport in health and disease. J Intern Med. Brown GK. Glucose transporters: structure, function and consequences of deficiency. J Inherit Metab Dis.

Kidney Int Suppl. Wright EM. Am J Physiol Renal Physiol. Molecular physiology of sodium-glucose cotransporters. Physiol Rev. Silverman M, Turner JR.